ARISTOTLE试验:房颤患者口服抗凝前纤维蛋白凝块溶解时间与出血的关系
ARISTOTLE试验纳入1841例未接受抗凝治疗的房颤患者,在启动研究药物前检测血浆纤维蛋白凝块溶解时间。结果显示,较短的溶解时间独立预测更高的出血风险,主要及临床相关非主要出血在最短四分位组显著多于最长四分位组,且阿哌沙班与华法林的治疗分配不影响该关系。
要点
- 房颤患者抗凝前纤维蛋白凝块溶解时间较短与出血风险升高独立相关。
- 最短四分位组主要及临床相关非主要出血年发生率为6.3%,最长四分位组为2.1%。
- 溶解时间与心血管死亡、卒中、系统性栓塞或心肌梗死复合终点无显著关联。
核心结论
- 抗凝治疗前纤维蛋白凝块溶解时间较短可独立预测房颤患者口服抗凝后的更高出血风险。
研究设计与样本
- ARISTOTLE试验中,对1841例未接受抗凝治疗的房颤患者,在启动研究药物前获取血浆样本,行纤维蛋白凝块浊度检测并确定溶解时间,按溶解时间四分位(Q1至Q4,从最短到最长)分析其与特征、生物标志物及治疗期间出血和心血管事件的关系。
主要发现
- Q2和Q3组出血风险介于Q1与Q4之间[HR分别为2.21(1.27-3.87)和2.08(1.18-3.66)],提示存在渐变效应。
- 溶解时间与心血管死亡、卒中、系统性栓塞或心肌梗死的复合终点无显著关联。
- 较短的溶解时间与年龄较大、男性、永久性房颤、较低体重指数、较低估算肾小球滤过率和C反应蛋白以及较高N末端B型利钠肽原相关。
临床怎么用
- 对于房颤患者,抗凝前检测纤维蛋白凝块溶解时间可能有助于识别出血高风险个体,但需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Oral anticoagulation reduces stroke risk in patients with atrial fibrillation (AF) but increases bleeding. Longer fibrin clot lysis time has been shown to predict adverse cardiovascular outcomes in acute coronary syndromes. This study explored relationships between fibrin clot lysis time at randomization and clinical outcomes in patients with AF enrolled in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in AF (ARISTOTLE) trial. METHODS: Plasma samples were obtained from anticoagulation-naïve participants, before initiation of study medication (n = 1841). Fibrin clot turbidimetry was performed, and lysis time determined. Associations between lysis time and characteristics, biomarkers, and on-treatment bleeding and cardiovascular events were assessed by lysis time quartile (Q1-4, shortest to longest). RESULTS: A shorter lysis time was associated with being older, male, permanent AF, lower body mass index, estimated glomerular filtration rate and C-reactive protein, and higher N-terminal pro-B-type natriuretic peptide. Major and clinically relevant non-major bleeding was significantly more frequent in lysis time Q1 vs. Q4 [6.3%/yr vs. 2.1%/yr; HR, 2.99 (95% CI, 1.75-5.12); P = .001], including after multifactorial adjustment [HR, 2.61 (1.45-4.69); P = .016]. Those in Q2 and Q3 had intermediate bleeding risk vs. Q4 [HR, 2.21 (1.27-3.87); 2.08 (1.18-3.66) respectively], suggesting a graduated effect. Treatment allocation to apixaban vs. warfarin did not affect the relationship between lysis time and bleeding (interaction-P = .80). There was no significant association between lysis time and a composite of cardiovascular death, stroke, systemic embolism or myocardial infarction. CONCLUSIONS: Shorter pre-treatment fibrin clot lysis time independently predicted higher bleeding risk in patients receiving oral anticoagulation for AF.
引用
- Parker, Nelson, Lee, et al. Pre-treatment lysis time of plasma-derived fibrin clots and bleeding in patients on oral anticoagulants for atrial fibrillation in the ARISTOTLE trial. Eur Heart J. 2026. PMID: 40444814. doi:10.1093/eurheartj/ehaf347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。